CTLA-4 blockade has shown durable results in many types of cancer including melanoma, NSCLC, and renal cell carcinoma (RCC), possibly secondary to intratumoral Treg depletion [75, 96, 97]. Here, CTLA4 is linked to non-small cell lung carcinoma.